European Medicines Agency (EMA) grants Orphan Drug Designation to Kedrion's plasma-derived treatment for Congenital Aceruloplasminemia, a rare genetic disorder of iron metabolism
CASTELVECCHIO PASCOLI, Italy, Nov. 27, 2025, 04:00 GMT-05
Kedrion-ACP
Read full article →